Re-mark
Intratumoral Cancer Therapy Market Analysis As per DelveInsight, with an anticipated approval of the therapies the Intratumoral cancer market is expected to gain major traction that is estimated to soar significantly at a CAGR of 43% during the forecast period 2021-30 in the 7MM. Further, in the 7MM, the USA is expected to capture the maximum chunk of the Intratumoral cancer therapy market share. Key companies such as Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, and others are developing novel Intratumoral cancer therapies expected to enter the market soon.
